Effects of selective and non‐selective cyclo‐oxygenase inhibition on endothelial function in patients with rheumatoid arthritis

Wong, Melinda; Jiang, Benyu; McNeill, Karen; Farish, Stephen J.; Kirkham, B. W.; Chowienczyk, Phil

doi:10.1080/03009740701286771

Cited by 22 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Not only biological disease modifiers but also statins such as atorvastatin and simvastatin have shown efficacy in improving endothelial dysfunction in RA patients, which is attributed to a decrease in proatherogenic lipids, oxidative stress markers, and inflammatory markers CRP and TNFa (24,25). However, it has been reported recently that short-term (2 weeks) treatment with selective and non-selective cyclooxygenase inhibitors does not improve endothelial dysfunction in RA patients (26). The results of the present study may also be due to inhibition of proinflammatory cytokines by spironolactone.…”

Section: Discussioncontrasting

confidence: 64%

Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis

Syngle

Vohra

Kaur

et al. 2009

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 64%

Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis

Syngle

Vohra

Kaur

et al. 2009

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…On average, 78% of the patients were female (range 69–91%). Except for 1 trial (46), all trials were sponsored by the pharmaceutical industry. According to the Thomson Reuters Micromedex 1.0 recommended dosage for RA, 10 of the 54 randomized comparisons used a dose above the recommended dose, 39 used the recommended dose, and 5 used a dose below the recommended dose.…”

Section: Resultsmentioning

confidence: 99%

Effect of nonsteroidal antiinflammatory drugs on the C‐reactive protein level in rheumatoid arthritis: A meta‐analysis of randomized controlled trials

Tarp¹,

Bartels²,

Bliddal³

et al. 2012

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To evaluate the effects of oral nonsteroidal antiinflammatory drugs (NSAIDs) on Creactive protein (CRP) levels in rheumatoid arthritis (RA) patients, with a prespecified focus on the different NSAIDs.Methods. We performed a systematic search in Medline via PubMed, the Cochrane Central Register of Controlled Trials, EMBase via OVID, the Institute for Scientific Information Web of Science, and other sources. Eligible trials were parallel-group, randomized, placebo-controlled trials of oral NSAID therapy in RA patients for which there were extractable CRP data. Standardized mean differences (SMDs) with 95% confidence intervals (95% CIs) were calculated from the differences in means of CRP levels between groups (active treatment minus placebo) divided by the pooled SDs. For the meta-analysis, a random-effects model was used to estimate the overall change in CRP level, and stratified analysis was used to examine differences among NSAIDs.Results. We included 19 trials of 10 different NSAIDs. Overall, NSAIDs showed no effect on the CRP level ( Conclusion. Overall, NSAIDs have no effect on the CRP level. However, the nonselective NSAID naproxen was associated with a significant decrease in the CRP level, whereas the cyclooxygenase 2-selective NSAID lumiracoxib was associated with a significant increase in the CRP level. This finding is interesting considering the suspected influence of NSAIDs on cardiovascular complications.

show abstract

“…However, COX2 inhibitors and nonsteroidal anti-inflammatory drugs have recently been shown to up-regulate NOX(s) and increase ROS in blood vessel and heart (Li et al, 2008). Despite this explanation of the results, it should be noted that the precise mechanism(s) for regulation of NOX by either agent is not well understood and that the clinical effect of COX2 inhibitors on endothelial function is controversial and may depend on the study population (Chenevard et al, 2003;Widlansky et al, 2003;Wong et al, 2007). The role of blood pressure in the protective effects of p38 MAPK inhibitors was investigated by assessing the effects of a blood pressure neutral low dose and a higher dose that abolished the hypertension induced by the SFD.…”

mentioning

confidence: 98%

Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease

Willette

Eybye²,

Olzinski³

et al. 2009

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The evidence is compelling for a role of inflammation in cardiovascular diseases; however, the chronic use of anti-inflammatory drugs for these indications has been disappointing. The recent study compares the effects of two anti-inflammatory agents [cyclooxygenase 2 (COX2) and p38 inhibitors] in a model of cardiovascular disease. The vascular, renal, and cardiac effects of 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one (rofecoxib; a COX2 inhibitor) and 6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide [GSK-AHAB, a selective p38 mitogen-activated protein kinase (MAPK) inhibitor], were examined in the spontaneously hypertensive stroke-prone rat (SHR-SP). In SHR-SPs receiving a salt-fat diet (SFD), chronic treatment with GSK-AHAB significantly and dose-dependently improved survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuated dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1␤ (IL-1␤). In contrast, chronic treatment with a COX2-selective dose of rofecoxib exaggerated the harmful effects of the SFD, i.e., increasing vascular and renal dysfunction, dyslipidemia, hypertension, cardiac hypertrophy, PRA, aldosterone, and IL-1␤. The protective effects of a p38 MAPK inhibitor are clearly distinct from the deleterious effects of a selective COX2 inhibitor in the SHR-SP and suggest that anti-inflammatory agents can have differential effects in cardiovascular disease. The results also suggest a method for evaluating long-term cardiovascular efficacy and safety.

show abstract

Effects of selective and non‐selective cyclo‐oxygenase inhibition on endothelial function in patients with rheumatoid arthritis

Abstract: This study suggests that COX inhibition by indomethacin or rofecoxib do not improve endothelial function in patients with RA.

Cited by 22 publications

References 15 publications

Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis

Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis

Effect of nonsteroidal antiinflammatory drugs on the C‐reactive protein level in rheumatoid arthritis: A meta‐analysis of randomized controlled trials

Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease

Contact Info

Product

Resources

About